ReviewInternational journal of chronic obstructive pulmonary disease2012
Lung microbiology and exacerbations in COPD.
Review in International journal of chronic obstructive pulmonary disease, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 5 syntheses or guidelines pooled it, 165 citations in OpenAlex.
- Pooled it
- Proton pump inhibitors for chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2020Pooled it
- Bacterial infections in acute exacerbation of chronic obstructive pulmonary disease: a systematic review and meta-analysis.Infection · 2020Pooled it
- Head-to-head oral prophylactic antibiotic therapy for chronic obstructive pulmonary disease.The Cochrane database of systematic reviews · 2019Pooled it
- Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).The Cochrane database of systematic reviews · 2018Pooled it
- Sputum colour charts to guide antibiotic self-treatment of acute exacerbation of chronic obstructive pulmonary disease: the Colour-COPD RCT.Health technology assessment (Winchester, England) · 2025Trial
- Decreased expression of type I (IFN-β) and type III (IFN-λ) interferons and interferon-stimulated genes in patients with chronic rhinosinusitis with and without nasal polyps.The Journal of allergy and clinical immunology · 2019Trial
- Blocking AGEs reduces airway epithelial viral susceptibility in diabetes-exacerbated COPD.EMBO molecular medicine · 2026Article
- Epithelial cells in chronic obstructive pulmonary disease exacerbations: Targets for lung repair.Pharmacological reviews · 2026Review
- Clinical diagnostic value of targeted next generation sequencing for lower respiratory tract infection: a retrospective study.Frontiers in cellular and infection microbiology · 2026Article
- Prehospital respiratory interventions during six waves of COVID-19: results from Israel's Emergency Medical Services system.BMC emergency medicine · 2025Article
- Analysis of the bronchoalveolar lavage fluid microbial flora in COPD patients at different lung function during acute exacerbation.Scientific reports · 2025Article
- Risk Factors for Acute Exacerbation in Patients with COPD Group E in Ningbo: Risk Analysis of Irregular Review, Cardiovascular Complications, and Lung Function Decline.International journal of chronic obstructive pulmonary disease · 2025Article
- Incidence and Risk Factors of Tuberculosis-Associated Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2025Article
- Insights into human respiratory microbiome under dysbiosis and its analysis tool.Frontiers in microbiomes · 2025Review
- Bronchial epithelial cell-derived extracellular vesicles drive inflammasome activation andFrontiers in immunology · 2025Article
- A Systematic Review of the Pulmonary Microbiome in Patients with Acute Exacerbation COPD Requiring ICU Admission.Journal of clinical medicine · 2024Review
- Microbial variations in sputum cultures among hospitalized patients with community-acquired pneumonia: differences in sputum microbiota between asthma and COPD patients.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024Article
- Increased Red Blood Cell Distribution Predicts Severity of Chronic Obstructive Pulmonary Disease Exacerbation.Journal of personalized medicine · 2023Article
- Low human beta-defensin-2 levels in the sputum of COPD patients are associated with the risk of exacerbations.BMC pulmonary medicine · 2023Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Chronic obstructive pulmonary disease (COPD) is the most common chronic respiratory condition in adults and is characterized by progressive airflow limitation that is not fully reversible. The main etiological agents linked with COPD are cigarette smoking and biomass exposure but respiratory infection is believed to play a major role in the pathogenesis of both stable COPD and in acute exacerbations. Acute exacerbations are associated with more rapid decline in lung function and impaired quality of life and are the major causes of morbidity and mortality in COPD. Preventing exacerbations is a major therapeutic goal but currently available treatments for exacerbations are not very effective. Historically, bacteria were considered the main infective cause of exacerbations but with the development of new diagnostic techniques, respiratory viruses are also frequently detected in COPD exacerbations. This article aims to provide a state-of-the art review of current knowledge regarding the role of infection in COPD, highlight the areas of ongoing debate and controversy, and outline emerging technologies and therapies that will influence future diagnostic and therapeutic pathways in COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.